Aurinia Pharmaceuticals Inc. (AUPH) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Aurinia Pharmaceuticals reported revenue of $283.1M, up 20.4% from $235.1M the year before. Net income was $287.2M (a 101.5% net margin), or $2.07 per diluted share. Gross margin was 88.5% and operating margin was 37.1%. Operating activities generated $135.7M of cash. At fiscal year end, Aurinia Pharmaceuticals held $751.6M in total assets against $170.3M in total liabilities, including $80.2M of cash and equivalents.
Open the full interactive Aurinia Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Aurinia Pharmaceuticals Key Stats
| Share Price | $16.36 |
|---|---|
| Market Cap | $2.18B |
| P/E Ratio | 7.9 |
| Revenue YoY Growth | +20.4% |
| 52-Week Range | $11.10 – $18.62 |
| Shares Outstanding | 130.1 million (basic, 2026 Q2) |
Aurinia Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $50.1M | $45.6M | $134.0M | $175.5M | $235.1M | $283.1M |
| Cost of Goods Sold | — | $226.3M | $245.5M | $267.2M | — | — |
| Gross Profit | — | $44.5M | $128.4M | $161.4M | $206.9M | $250.4M |
| Operating Income | -$104.3M | -$180.7M | -$111.5M | -$91.7M | -$4.7M | $104.9M |
| Pre-Tax Income | -$102.8M | -$180.2M | -$106.4M | -$77.5M | $7.4M | $114.2M |
| Income Tax | -$94,000 | $760,000 | $1.8M | $551,000 | $1.7M | -$173.0M |
| Net Income | -$102.7M | -$181.0M | -$108.2M | -$78.0M | $5.8M | $287.2M |
| Diluted EPS | -$0.87 | -$1.40 | -$0.76 | -$0.54 | $0.04 | $2.07 |
Aurinia Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $73.5M | $77.1M | $77.7M | $83.2M |
| Net Income | $31.6M | $210.8M | $34.4M | $37.4M |
| Diluted EPS | $0.23 | $1.52 | $0.25 | $0.28 |
Aurinia Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $272.4M | $231.6M | $94.1M | $48.8M | $83.4M | $80.2M |
| Current Assets | $419.4M | $513.3M | $442.5M | $424.8M | $446.6M | $492.0M |
| Total Assets | $463.7M | $543.4M | $470.9M | $548.1M | $550.6M | $751.6M |
| Current Liabilities | $32.0M | $40.6M | $46.1M | $77.2M | $97.8M | $93.7M |
| Total Liabilities | $55.9M | $64.3M | $65.4M | $170.1M | $173.2M | $170.3M |
| Shareholders' Equity | $407.8M | $479.1M | $405.4M | $378.0M | $377.5M | $581.3M |
Aurinia Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$69.9M | -$157.7M | -$79.5M | -$33.5M | $44.4M | $135.7M |
| Cash From Investing | -$158.2M | -$103.9M | -$60.6M | -$6.7M | $39.3M | -$32.8M |
| Cash From Financing | $194.4M | $221.1M | $2.4M | -$5.1M | -$49.1M | -$106.1M |
Figures from Aurinia Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Aurinia Pharmaceuticals financials page for every line item.
Aurinia Pharmaceuticals Company Profile
| Ticker | AUPH |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Edmonton, Alberta, Canada |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001600620 |
Frequently Asked Questions
What was Aurinia Pharmaceuticals' revenue in fiscal 2025?
Aurinia Pharmaceuticals (AUPH) reported revenue of $283.1M for fiscal 2025.
What is Aurinia Pharmaceuticals' annual revenue history?
Aurinia Pharmaceuticals' annual revenue by fiscal year: 2020: $50.1M; 2021: $45.6M; 2022: $134.0M; 2023: $175.5M; 2024: $235.1M; 2025: $283.1M.
What was Aurinia Pharmaceuticals' net income in fiscal 2025?
Aurinia Pharmaceuticals reported net income of $287.2M for fiscal 2025.
What was Aurinia Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Aurinia Pharmaceuticals' diluted EPS was $2.07 for fiscal 2025 (adjusted for any later stock splits).
What was Aurinia Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Aurinia Pharmaceuticals reported revenue of $83.2M.
How many shares of Aurinia Pharmaceuticals are outstanding?
Aurinia Pharmaceuticals reported a weighted average of 130.1 million basic shares outstanding in 2026 Q2.
What is Aurinia Pharmaceuticals' market cap?
Based on its latest closing price, Aurinia Pharmaceuticals (AUPH) has a market capitalization of about $2.18B.
When does Aurinia Pharmaceuticals' fiscal year end?
Aurinia Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Aurinia Pharmaceuticals headquartered?
Aurinia Pharmaceuticals lists its business address in Edmonton, Alberta, Canada in its SEC filings.